# Research on individualized drug sensitivity detection technology based on bio-3D printing technology for precision treatment of gastrointestinal stromal tumors

## TL;DR

This study explores using 3D-printed tumor models to guide personalized treatment for gastrointestinal stromal tumors, showing improved patient outcomes.

## Contribution

The novel use of bio-3D printing to create patient-specific tumor models for drug sensitivity testing in gastrointestinal stromal tumors.

## Key findings

- 3D-printed tumor models retained histological features of original tumors, as shown by immunofluorescence staining.
- Patients treated with personalized drug plans based on 3D models had a longer median progression-free survival (6.1 months) compared to standard treatment (5.3 months).
- The difference in progression-free survival was statistically significant (P-value < 0.05).

## Abstract

This study aims to analyze and explore whether tumor biological three-dimensional printing (3DP) models can serve as reliable preclinical model research tools and assist in the personalized treatment of gastrointestinal stromal tumor (GIST) patients. Ten GIST cases admitted to our hospital from May 2024 to September 2024 were included in the personalized treatment group. Patient-derived GIST 3DP models were established, and treatment plans were selected based on the results of drug sensitivity tests. The progression-free survival (PFS) of the personalized treatment group was compared with that of GIST patients who had progressed after first-line treatment and were admitted to our hospital before the study. Treatment safety was also assessed. Immunofluorescence staining technology was used to observe tumor markers in the 3DP tumor models and their corresponding parent tumor tissues, revealing a high degree of consistency, which indicates that the 3DP tumor models highly retain the histological characteristics of the parent tumor tissues. The median PFS of patients in the personalized treatment group was 6.1 months, compared to 5.3 months in the previous treatment group, with a statistically significant difference (P-value <0.05). The individualized drug sensitivity detection technology based on bio-3D printing technology, used for the personalized treatment of GIST patients who have progressed after first-line treatment, can benefit patients.